Selected article for: "Clostridium difficile infection and difficile infection"
Author: Chi Heem Wong; Kien Wei Siah; Andrew W Lo
Title: Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics
  • Document date: 2020_4_14
    • ID: fnrm6a79_29
    Snippet: For non-industry-sponsored non-vaccine development programs, the overall PoS is 8.2% (SE: 0.6%) while PoS12, PoS23, and PoS3A are 61.0% (SE: 0.9%), 65.2% (SE: 1.2%), and 30.0% (SE: 1.8%), respectively (see Figure 5b) . The top three indications with the highest overall success rates for non-industry-sponsored non-vaccine development programs are CMV infection (23.5%, SE: 5.9%), clostridium difficile (20.5%, SE: 6.5%), and sepsis (17.4%, SE: 2.6%).....
    Document: For non-industry-sponsored non-vaccine development programs, the overall PoS is 8.2% (SE: 0.6%) while PoS12, PoS23, and PoS3A are 61.0% (SE: 0.9%), 65.2% (SE: 1.2%), and 30.0% (SE: 1.8%), respectively (see Figure 5b) . The top three indications with the highest overall success rates for non-industry-sponsored non-vaccine development programs are CMV infection (23.5%, SE: 5.9%), clostridium difficile (20.5%, SE: 6.5%), and sepsis (17.4%, SE: 2.6%). . CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cc international license and development program: 1
    • cc international license and international license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc international license and non industry: 1, 2, 3, 4
    • cc international license and overall pos: 1, 2, 3
    • clostridium difficile and CMV infection: 1
    • clostridium difficile and overall pos: 1
    • clostridium difficile and success rate: 1
    • CMV infection and international license: 1
    • CMV infection and non industry: 1
    • CMV infection and overall pos: 1, 2, 3
    • CMV infection and SE CMV infection: 1
    • development program and international license: 1
    • development program and non industry: 1, 2, 3
    • development program and non vaccine development program: 1
    • development program and overall pos: 1, 2
    • development program and success rate: 1
    • international license and non industry: 1, 2, 3, 4
    • international license and overall pos: 1, 2, 3
    • non industry and SE CMV infection: 1